Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-week, placebo-controlled Phase III study (PRECISE 1) - Sandborn,W.J.; Feagan,B.G.; Stoinov,S. (J Gastroenterol, 2006)